Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war

The game is on for TROP2 antibody-drug conjugates in first-line triple-negative breast cancer. | Less than a month after an approval for Daiichi Sankyo and AstraZeneca’s Datroway for front-line TNBC patients who are not candidates for PD-1/L1 inhibitors, the FDA has handed Gilead’s Trodelvy a rivaling approval that allows the drug to be used regardless of patients’ PD-L1 status.